Lipid-lowering drug use and breast cancer in older women: A prospective study
Lipid-lowering drug use and breast cancer in older women: A prospective study
复制标题
DOI：
10.1089/154099903322447710
复制
发表时间：
2003-10-01
影响因子：
3.5
通讯作者：
Bauer, DC
中科院分区：
文献类型：
--
作者：
Cauley, JA;Zmuda, JM;Bauer, DC
目的：检验以下假设：使用降低脂质药物会降低老年妇女的乳腺癌风险。平均年龄77岁。主要结局措施是通过病历和病理报告证实的乳腺癌，平均为6.8岁（244例）。清单：576名妇女（7.7％）报告了使用降低脂质药物的使用。在他汀类药物使用者中，乳腺癌年龄调整后的发生率为3.1/1000人年，使用其他降低脂质剂的女性为1.4，在非使用者中为5.0。调整年龄和体重后，他汀类药物使用者的乳腺癌的相对风险（RR）为0.28（95％置信区间[CI] 0.09-0.86），在使用其他降低脂质药物的女性中，它为0.37（与非使用者相比，95％CI 0.14-0.99）。降低脂质的吸毒者组合的组合降低了乳腺癌的风险68％（95％CI 32％-85％）。进一步调整激素使用，乳腺癌的家族史，乳房摄影或其他危险因素并没有改变结果。结论：使用降低脂质药物的老年妇女可能会降低患乳腺癌的风险。鉴于在老年妇女中汀类药物的广泛使用，这些结果可能会对公共卫生产生巨大影响。但是，这些发现需要在其他前瞻性研究中确认，因为它们基于少量乳腺癌事件。
Objective: To test the hypothesis that use of lipid-lowering drugs reduces the risk of breast cancer in older women.Methods: This was a multicenter prospective cohort study conducted at four community-based clinical centers in the United States, including 7528 Caucasian women, mean age 77 years. The main outcome measure was incident breast cancer confirmed by medical record and pathology reports identified over an average of 6.8 years (244 cases).Results: The use of lipid-lowering drugs was reported by 576 women (7.7%). The age-adjusted incidence of breast cancer was 3.1/1000 person-years among statin users, 1.4 among women using other lipid-lowering agents, and 5.0 among nonusers. After adjustment for age and body weight, the relative risk (RR) of breast cancer among statin users was 0.28 (95% confidence intervals [CI] 0.09-0.86), and among women who used other lipid-lowering drugs, it was 0.37 (95% CI 0.14-0.99) in comparison to nonusers. The combined group of lipid-lowering drug users had a 68% reduction in the risk of breast cancer (95% CI 32%-85%). Further adjustment for hormone use, family history of breast cancer, mammography use, or other risk factors did not alter the results.Conclusions: Older women who use lipid-lowering drugs may have a reduced risk of breast cancer. Given the widespread use of statins in older women, these results could have a large public health impact. However, these findings need confirmation in other prospective studies, as they were based on a small number of breast cancer events.